Abstract
Influenza is a common respiratory virus that could cause death. Vaccination of influenza was recommended in many countries to reduce the heavy disease burden in every flu season. In this study, we applied a simulation model to estimate the economic outcomes of influenza vaccination among adolescents in the United States in 2024. In this study, we use the competing choice method to compare the costeffectiveness of vaccination and no vaccination. We divide the cohort group into the younger age group (10-14) and the elder age group (15- 19). We use the estimation of net cost and net quality-adjusted life years (QALYs) to calculate the incremental cost-effectiveness ratios (ICER) of influenza vaccination in three different coverage of 50%, 80%, and 100% in 2024. The result shows the highest cost-effectiveness for 80% coverage and younger age group, and the largest health benefit for 100% coverage among adolescents from 10 to 19 in the US in 2024.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
